Thank you, Mike.
to are; CMS Our XXXX activity sales distribution expand offering and goals insurance to with move breakeven towards product via more along our in to and leverage achieve profitable activities these two, for Germany, acquisition, adding commercial VA our capital. current our one, to with operations growth and to
and be lines. drivers advancements build progress will VA expansion of the with XXXX the growth direct systems US with upon sales technical of regulatory product and with internal program and the Medicare the through CMS, the growth of Germany, to more The addition in company centers. placement supply will ReWalk of with Other expansion on Exoskeleton
progress optimal measure and one, qualifying are XXXX, infrastructure processing I like is will CMS. use product. approach selection our have To ensure to for other to our claims company with the highlight. These extensive the CMS become to regional the Number I’d areas in MACs requirements building with expected patient user, benefit of within This the submissions, the insurers case seven of of and we expansion ReWalkers. CMS, successful submissions successful are
target building infrastructure XX.X% comprised of which SOP, cord a XX% between coverage spinal market approximately to younger to in in and XXXX an expand under was injury in CMS our XX another XXXX, injury and are years the cord XXXX. Until submissions XX the that approximately VA injury occurs the Medicare, XXXX US cord under will late of XX.X% significantly spinal to by market. in post-injury We covered population five is covered Medicaid. Spinal limited
progress to contacts We larger to us also develops. and CMS new will audience. develop These anticipate with the a market the by be begin allow the as private access insurers this will with to private considered activities market we payers
As unlikely unwilling was that an accessible a to have example, to product coverage write been with prescription many we individual. via clinicians to speak be the for a
With ambulate through development becoming system. want others is allow for to and who Exoskeleton realistic, which their this referring patients an access will of coverage to technology expanding CMS with the
re-qualified CMS over have previously currently being that leads are We for XXX screened submissions.
high period the a as lead group. Our this risk population very was pandemic is base in limited
will to efforts leaders. digital our with We by shows, key gathering lead referral and now building trade opinion through promotion efforts seek expand
Number of expansion centers. two, VA training
and the [VMACs] medical VA active centers, becoming post-COVID. increasingly are As the [ph] resources
There XXXX. more reliable over And be are both United use is to manage number We States. are the groups in that with goal centers remainder geographic the that expand by and least the conduct three and the or of active can qualified at calendar veterans. contracted the for VMACs training, community-based actively working may conveniently closely the our VA expand year and of six that qualify of to the provider Exoskeleton currently
to seek of acceptance drug the direct add now proceedings. a Number groups post supply to three. our that we’re In from the additional will we Germany, contracts Court supply the
working with We must promotion, reestablish and digital societies, our base also post-COVID trade the reemergence in a XXXX. of lead with in local full shows shift towards
product four, Number acquisition.
considerations the that a entities The and and strategy the within operating product that efforts. neuro adjacent, clinics we and with interest that for in financially identified have accretive, These advanced lines a high benefit these a infrastructure would to completing technologies banking analysis, considerations transaction and patient We the support the on priority, work from have partner consolidated focused rehabilitation. enterprise and is profile have community. assisting have and
as reach conclusions. We will they initiatives report these on
ReWalker then a curb, or significant home walking curb a a product five, visiting where exists that user or they with Examples limitation prevents improvements. friend’s and elevators or A is or include stairs organic when access. Number cutouts, available. a are ramps steps locations stairs, not encounter
under function Addition is submission in our curb/stair review at of FDA the XXXX. the from
We a review. to have to launch additional is are full for completing prospectively a request the programs responded successful This information training subject preparing in FDA’s FDA in XXXX. and
the On system, of preparation submission. final finalization late-stage next in advancements FDA ReWalk of and are the we for development
review We the expect second XXXX. for to in and CE half FDA review submit this of
Number data expansion. six,
known comparison AFOs. study a For our system plantarflexion-focused the supporting stroke of ankle-foot to technologies, as motor existing commonly technology of of technology independent the a the cable-driven designs, and we are orthoses
named has technology, Our targeted design been use ReBoot. the ReHome based community
would been since previously by been longer coverage that That considered. no and program that Medicare innovative included pathway for Government at likely being a have have But that the this is deferred we design. designation replacement the coverage some programs are expect We has breakthrough time. US granted path
This As our may benefit covered is randomized demonstrates AFO. codes design conducted larger this technical innovation of company-sponsored be study existing of this data pilot consideration if we a support the we a believe trial. over reimbursement a review, have parallel to clinical within an initial
wheelchair SCI published VA the supported That presented medical considering and XXXX. matched grant of to during be ReWalk product, Ambulator our For will outcome data to ReWalk a of we a costs profile the medical the a user.
seven, number the company. the patient includes growth complete and further provide definitions XXXX investment reimbursement in to processing access provide infrastructure the to to financially, And allow submission to for
have investor community. support to In increased investment communication addition, we as investment broaden our our to to the and mission relations expand, and the position reach
accepted, growth core and neuro that broader will to access In capital. SCI the the both are level for insurance direction and understand and build is in is and needs breakeven on and clinic consolidator as profitability to line as with conclusion, rehabilitation. meet create current widely strategic to in succeed community mass this the critical We our overall expansion the our to seeking product more a of
and our results I wish to they the and XXXX. the the and upon We’re also going thank direction, building right thank life-changing business this updates for continued support in further commitment forward their we XXXX. to to team XXXX technologies as them in in are look I their these during XXXX. providing for base I and shareholder how expand supporting wish in XXXX
we we’re operator, if take all move to point, process. this prepared At and answer that questions to can
